Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor
Giuseppe Lamberti(Dana-Farber Cancer Institute), Davide Campana(University of Bologna), Antongiulio Faggiano(European Neuroendocrine Tumor Society), Salvatore Tafuto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Chiara De Divitiis, Sara Massironi(Azienda Ospedaliera San Gerardo), Anna La Salvia(Ospedale San Luigi Gonzaga), Roberta Modica(University of Naples Federico II), Manuela Albertelli(Ospedale Policlinico San Martino), Sara Pusceddu(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Panzuto(Sapienza University of Rome), Alberto Bongiovanni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Diego Ferone(Ospedale Policlinico San Martino), Toni Ibrahim(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Maria Pia Brizzi(Ospedale San Luigi Gonzaga), Giuseppe Badalamenti(University of Palermo), Martina Torchio(Azienda Socio Sanitaria Territoriale di Pavia), Fabio Gelsomino(University of Modena and Reggio Emilia), Nicole Brighi(London Cancer), Annamaria Colao(Federico II University Hospital), Giovanni Butturini(University of Verona), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 41
Related Papers
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
|Clinical Endocrinology|2006|830
Guidelines for Acromegaly Management: An Update
|The Journal of Clinical Endocrinology & Metabolism|2009|763